Skip to main content

Sign In or Register Today to Access This Content

micro-community-banner
 
Profile Image
  • Saved

made a Post

60-year-old Female with Dyspnea

A 60-year-old female patient presents at her primary care physician’s office complaining of dyspnea. Her medical history is unremarkable save for the fact .....

  • Saved

made a Post

CD4  T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

CD4 T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy

Source : https://cancerimmunolres.aacrjournals.org/content/8/3/334

Accumulating evidence indicates that CD8 T cells in the tumor microenvironment and systemic CD4 T-cell immunity play an important role in mediating durable antitumor responses. We longitudinally examined .....

  • Saved

made a Post

B cell-Derived IL35 Drives STAT3-Dependent CD8  T-cell Exclusion in Pancreatic Cancer

B cell-Derived IL35 Drives STAT3-Dependent CD8 T-cell Exclusion in Pancreatic Cancer

Source : https://cancerimmunolres.aacrjournals.org/content/8/3/292

Pancreatic ductal adenocarcinoma (PDA) is an aggressive malignancy characterized by a paucity of tumor-proximal CD8 T cells and resistance to immunotherapeutic interventions. Cancer-associated mechanisms that elicit CD8 T-cell .....

  • Saved

made a Post

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis

Treatment-Related Adverse Events of Combination Immune Checkpoint Inhibitors: Systematic Review and Meta-Analysis

Source : https://doi.org/10.3389/fonc.2020.00258

Background: Although clinical practice guidelines for the management of Immune Checkpoint Inhibitor (ICI)-related adverse events have recently been published, precise and nuanced toxicity data for combination ICI therapy are lacking. .....

  • Saved

made a Post

LAG-3 and PD-1 LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

LAG-3 and PD-1 LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures

Source : https://doi.org/10.1080/2162402X.2020.1736792

ABSTRACT Despite the success of immunotherapy using checkpoint blockade, many patients with solid tumors remain refractory to these treatments. In human cancer, the experimental options to investigate the specific effects .....

  • Saved

made a Post

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk

Macrophage and Tumor Cell Cross-Talk Is Fundamental for Lung Tumor Progression: We Need to Talk

Source : https://doi.org/10.3389/fonc.2020.00324

Regardless of the promising results of certain immune checkpoint blockers, current immunotherapeutics have met a bottleneck concerning response rate, toxicity, and resistance in lung cancer patients. Accumulating evidence forecasts that .....

  • Saved

made a Post

Intratumor Heterogeneity in Early Lung Adenocarcinoma

Intratumor Heterogeneity in Early Lung Adenocarcinoma

Source : https://doi.org/10.3389/fonc.2020.00349

Lung cancer is one of the deadliest diseases in the world and is the leading cause of cancer-related deaths. Among the histological types, adenocarcinoma is the most common, and it .....

  • Saved

made a Post

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma

A TP53-associated gene signature for prediction of prognosis and therapeutic responses in lung squamous cell carcinoma

Source : https://doi.org/10.1080/2162402X.2020.1731943

ABSTRACT The tumor-suppressor gene tumor protein p53 ( TP53) is one of the most commonly mutated genes in human lung cancer, and TP53 mutations are associated with a worsened prognosis .....

  • Saved

made a Post

On March 10, 2020, Takeda Pharmaceutical provided the following press release regarding their upfront phase 3 trial in newly diagnosed multiple myeloma patients of ixazomib/lenalidomide/dexamethasone versus lenalidomide/dexamethasone:

Takeda Pharmaceutical .....

  • Saved

made a Post

On March 9, 2020, the following press release was made by Bristol Myers Squibb (comments to follow):

March 09, 2020 06:59 AM Eastern Daylight Time
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers .....